Research programme: bispecific antibodies - Genmab/Janssen Biotech

Drug Profile

Research programme: bispecific antibodies - Genmab/Janssen Biotech

Alternative Names: Ab 957; BCMAxCD3 bispecific antibody; EM1-mAb DuoBody

Latest Information Update: 07 Feb 2017

Price : $50

At a glance

  • Originator Genmab; Janssen Biotech
  • Developer Genmab
  • Class Bispecific antibodies
  • Mechanism of Action Epidermal growth factor receptor modulators; Immunomodulators; Proto oncogene protein c met modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer

Most Recent Events

  • 03 Dec 2016 Pharmacodynamics data from a preclinical studies in Cancer presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
  • 03 Dec 2016 Janssen plans a phase I trial for Multiple myeloma
  • 14 Jul 2014 Preclinical trials in Autoimmune disorders in Denmark (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top